“Novartis and the Battle to Access Essential Drugs”

Source: Newsclick

This feature examines why India’s patenting regime, despite being pro-public in terms of promoting easier access to drugs, has faced considerable criticism, particularly post the Supreme Court decision in the Novartis case. The feature examines why India has put in place laws such as Section 3(d) of the Patents Act and explains how and why such provisions are essential to promote easier and cheaper access to essential drugs. The feature also addresses the numerous (often false) claims by pharma MNCs regarding pricing, innovation and research and development costs.

This entry was posted in Compulsory Licensing, Evergreening, Novartis Case, Patent examination system, Patents, Pricing, Sec 3 (d), TRIPS, WTO. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s